Literature DB >> 17938288

Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.

Nir Grabie1, Israel Gotsman, Rosa DaCosta, Hong Pang, George Stavrakis, Manish J Butte, Mary E Keir, Gordon J Freeman, Arlene H Sharpe, Andrew H Lichtman.   

Abstract

BACKGROUND: PD-L1 and PD-L2 are ligands for the inhibitory receptor programmed death-1 (PD-1), which is an important regulator of immune responses. PD-L1 is induced on cardiac endothelial cells under inflammatory conditions, but little is known about its role in regulating immune injury in the heart. METHODS AND
RESULTS: Cytotoxic T-lymphocyte-mediated myocarditis was induced in mice, and the influence of PD-L1 signaling was studied with PD-L1/L2-deficient mice and blocking antibodies. During cytotoxic T-lymphocyte-induced myocarditis, the upregulation of PD-L1 on cardiac endothelia was dependent on T-cell-derived interferon-gamma, and blocking of interferon-gamma signaling worsened disease. Genetic deletion of both PD-1 ligands [PD-L1/2(-/-)], as well as treatment with PD-L1 blocking antibody, transformed transient myocarditis to lethal disease, in association with widespread polymorphonuclear leukocyte-rich microabscesses but without change in cytotoxic T-lymphocyte recruitment. PD-L1/2(-/-) mice reconstituted with bone marrow from wild-type mice remained susceptible to severe disease, which demonstrates that PD-L1 on non-bone marrow-derived cells confers the protective effect. Finally, depletion of polymorphonuclear leukocytes reversed the enhanced susceptibility to lethal myocarditis attributable to PD-L1 deficiency.
CONCLUSIONS: Myocardial PD-L1, mainly localized on endothelium, is critical for control of immune-mediated cardiac injury and polymorphonuclear leukocyte inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938288     DOI: 10.1161/CIRCULATIONAHA.107.709360

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  102 in total

1.  Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

Authors:  James Randall Patrinely; Arissa C Young; Henry Quach; Grant R Williams; Fei Ye; Run Fan; Leora Horn; Kathryn E Beckermann; Erin A Gillaspie; Jeffrey A Sosman; Debra L Friedman; Javid J Moslehi; Douglas B Johnson
Journal:  Eur J Cancer       Date:  2020-06-27       Impact factor: 9.162

Review 2.  PD-1, gender, and autoimmunity.

Authors:  Ravi K Dinesh; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-28       Impact factor: 9.754

Review 3.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

4.  Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis.

Authors:  Timothy W Phares; Stephen A Stohlman; David R Hinton; Roscoe Atkinson; Cornelia C Bergmann
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

Review 5.  Cardiovascular Risk in Cancer Survivors.

Authors:  Inbar Agmon Nardi; Zaza Iakobishvili
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-28

Review 6.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

7.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

Review 8.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

9.  Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants.

Authors:  Antje Kroner; Nicholas Schwab; Chi Wang Ip; Sonja Ortler; Kerstin Göbel; Klaus-Armin Nave; Mathias Mäurer; Rudolf Martini; Heinz Wiendl
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

Review 10.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.